Covaxin is one of the three vaccines for which emergency approval has been sought from the Drug Controller General of India.
Hyderabad| India’s wait for the Covid-19 vaccine may get over soon. Indigenous Coronavirus Vaccine maker Bharat Biotech has made a major announcement in this regard. Phase-1 trials of results of the Covaxin have been published in the foreign journal Med-Archive (medRxiv). It claims that the vaccine is completely safe and effective. It has not caused any serious side-effects.
Covaxin is one of the three vaccines for which emergency approval has been sought from the Drug Controller General of India. In November itself, phase-3 trials have been started on 25,800 people at 25 sites across the country.
The Hyderabad-based company, Bharat Biotech, has developed this vaccine in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV). Phase-1 clinical trial was conducted to test the safety and immunogenicity of the BBV152 (Covaxin) vaccine. During this time 375 volunteers were placed in three groups. They were given different doses. Two doses were given with a difference of 14 days.
According to the report published in the journal, most volunteers had mild side-effects. These were also resolved soon. There was a serious side-effect report, but it turned out that it had nothing to do with the vaccine. All three groups showed very good and strong immune response. The results of different doses also did not show much difference. At the same time, the properties of elimination of some strains of coronavirus appeared in all volunteers.
The vaccine can be stored between 2 and 8 ° C.
Reports say that this vaccine can be stored between 2 to 8 degrees Celsius. This is in accordance with the cold chain requirements of the National Immunization Program.
Both formulations were selected for Phase-2 immunogenicity trials. Phase-2 trials of Covaxin are over. But its results have not been revealed yet.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
